MX2016007063A - Peptidos terapeuticos. - Google Patents
Peptidos terapeuticos.Info
- Publication number
- MX2016007063A MX2016007063A MX2016007063A MX2016007063A MX2016007063A MX 2016007063 A MX2016007063 A MX 2016007063A MX 2016007063 A MX2016007063 A MX 2016007063A MX 2016007063 A MX2016007063 A MX 2016007063A MX 2016007063 A MX2016007063 A MX 2016007063A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic peptides
- peptides
- mica
- polypeptide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención proporciona, en parte, composiciones que comprenden péptidos que se unen inmunoespecíficamente a secuencia A relacionada con polipéptido MHC clase I (MICA).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913198P | 2013-12-06 | 2013-12-06 | |
US201461953588P | 2014-03-14 | 2014-03-14 | |
PCT/US2014/068862 WO2015085210A1 (en) | 2013-12-06 | 2014-12-05 | Therapeutic peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016007063A true MX2016007063A (es) | 2016-09-06 |
MX371187B MX371187B (es) | 2020-01-22 |
Family
ID=52293185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007063A MX371187B (es) | 2013-12-06 | 2014-12-05 | Péptidos terapéuticos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10106611B2 (es) |
EP (1) | EP3077504B1 (es) |
JP (1) | JP6705746B2 (es) |
KR (1) | KR20160090904A (es) |
CN (1) | CN106029694A (es) |
AU (1) | AU2014360273A1 (es) |
BR (1) | BR112016012358A2 (es) |
CA (1) | CA2932767A1 (es) |
EA (1) | EA201691078A1 (es) |
ES (1) | ES2755129T3 (es) |
IL (1) | IL245744A0 (es) |
MX (1) | MX371187B (es) |
WO (1) | WO2015085210A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2925654T3 (es) | 2011-09-30 | 2022-10-19 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
AU2014228502A1 (en) | 2013-03-15 | 2015-08-20 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US9803017B2 (en) | 2013-07-05 | 2017-10-31 | University Of Washington Through Its Center For Commercialization | Soluble MIC neutralizing monoclonal antibody for treating cancer |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
CN114081946A (zh) | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10279021B2 (en) | 2014-03-14 | 2019-05-07 | Dana-Faber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US11066471B2 (en) | 2016-10-19 | 2021-07-20 | Novelogics Biotechnology Inc. | Antibodies to MICA and MICB proteins |
EP3532091A2 (en) * | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
CN108299557A (zh) * | 2017-01-13 | 2018-07-20 | 杭州翰思生物医药有限公司 | 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法 |
EP3577138A1 (en) | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
CA3053989A1 (en) | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lag-3 antibodies and uses thereof |
EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
CN109232738B (zh) * | 2017-07-11 | 2021-11-09 | 南京金斯瑞生物科技有限公司 | 一种抗人ox40单克隆抗体及其应用 |
US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
AU2019236865A1 (en) | 2018-03-23 | 2020-10-01 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
JP2021519771A (ja) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 腫瘍を処置する方法 |
WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
US20230296611A1 (en) | 2020-08-10 | 2023-09-21 | Innate Pharma | Cell surface mica and micb detection using antibodies |
CA3224182A1 (en) * | 2021-06-17 | 2022-12-22 | Fapon Biotech Inc. | Chimeric immunoglobulin |
CN113637077B (zh) * | 2021-10-14 | 2021-12-24 | 尚健单抗(北京)生物技术有限公司 | 一种抗mica的抗体及其应用 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
WO1988007054A1 (en) | 1987-03-18 | 1988-09-22 | Research Corporation Limited | Complement-binding peptide |
GB8709290D0 (en) | 1987-04-16 | 1987-05-20 | Secretary Trade Ind Brit | Precision motion slideways |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JP3345419B2 (ja) * | 1991-11-08 | 2002-11-18 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | Cd8結合ドメイン・ペプチド |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0937258A2 (en) | 1996-10-29 | 1999-08-25 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
WO2002068615A2 (en) | 2001-02-28 | 2002-09-06 | Fred Hutchinson Cancer Research Center, Inc. | Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives |
US6566208B2 (en) | 2001-07-25 | 2003-05-20 | Chartered Semiconductor Manufacturing Ltd. | Method to form elevated source/drain using poly spacer |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
AU2003225093A1 (en) | 2002-04-22 | 2003-11-03 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
ATE394674T1 (de) | 2002-04-22 | 2008-05-15 | Univ Florida | Funktionalisierte nanopartikel und verwendungsverfahren |
US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
DK1553975T3 (da) | 2002-09-27 | 2012-05-07 | Xencor Inc | Optimerede Fc-varianter og fremgangsmåder til generering heraf. |
PT1562972E (pt) | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
BRPI0506771A (pt) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | anticorpo, e, composição farmacêutica |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
ES2426816T3 (es) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
US20080148432A1 (en) | 2005-12-21 | 2008-06-19 | Mark Scott Abad | Transgenic plants with enhanced agronomic traits |
ES2371083T3 (es) | 2004-12-21 | 2011-12-27 | Medimmune Limited | Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos. |
PL2397156T3 (pl) * | 2005-06-08 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1) |
WO2007055926A1 (en) | 2005-11-03 | 2007-05-18 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
DE102006009847A1 (de) | 2006-03-01 | 2007-09-06 | Sweredjuk, Robert, Dr. | Verfahren von Absorbieren von Schadstoffen und Gerüchen |
CA2665090A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
CA2664567C (en) | 2006-10-04 | 2016-04-26 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
EP2150565A2 (en) | 2007-04-23 | 2010-02-10 | Fred Hutchinson Cancer Research Center | NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5 |
NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
EP2254602B1 (en) | 2008-02-13 | 2018-11-21 | President and Fellows of Harvard College | Continuous cell programming devices |
WO2011063336A2 (en) | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
US8207497B2 (en) | 2009-05-08 | 2012-06-26 | Ionsense, Inc. | Sampling of confined spaces |
KR101688522B1 (ko) | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
DK2658873T3 (da) * | 2010-12-27 | 2019-11-25 | Apo T B V | Tværbindende polypeptid omfattende et tetramerisk enkeltkæde-antistof, der binder et MHC-MAGE-kompleks, der inducerer apoptose |
US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
ES2925654T3 (es) | 2011-09-30 | 2022-10-19 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
CA2862101A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
AU2014228502A1 (en) | 2013-03-15 | 2015-08-20 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
-
2014
- 2014-12-05 CN CN201480075001.0A patent/CN106029694A/zh active Pending
- 2014-12-05 AU AU2014360273A patent/AU2014360273A1/en not_active Abandoned
- 2014-12-05 WO PCT/US2014/068862 patent/WO2015085210A1/en active Application Filing
- 2014-12-05 EA EA201691078A patent/EA201691078A1/ru unknown
- 2014-12-05 MX MX2016007063A patent/MX371187B/es active IP Right Grant
- 2014-12-05 US US15/100,060 patent/US10106611B2/en active Active
- 2014-12-05 CA CA2932767A patent/CA2932767A1/en not_active Abandoned
- 2014-12-05 JP JP2016536690A patent/JP6705746B2/ja active Active
- 2014-12-05 ES ES14824621T patent/ES2755129T3/es active Active
- 2014-12-05 EP EP14824621.8A patent/EP3077504B1/en active Active
- 2014-12-05 BR BR112016012358A patent/BR112016012358A2/pt not_active Application Discontinuation
- 2014-12-05 KR KR1020167017672A patent/KR20160090904A/ko not_active Application Discontinuation
-
2016
- 2016-05-19 IL IL245744A patent/IL245744A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3077504B1 (en) | 2019-08-14 |
BR112016012358A2 (pt) | 2017-09-26 |
IL245744A0 (en) | 2016-07-31 |
ES2755129T3 (es) | 2020-04-21 |
JP6705746B2 (ja) | 2020-06-03 |
JP2017501692A (ja) | 2017-01-19 |
AU2014360273A1 (en) | 2016-06-02 |
CA2932767A1 (en) | 2015-06-11 |
MX371187B (es) | 2020-01-22 |
WO2015085210A1 (en) | 2015-06-11 |
US10106611B2 (en) | 2018-10-23 |
EA201691078A1 (ru) | 2017-01-30 |
CN106029694A (zh) | 2016-10-12 |
US20170022275A1 (en) | 2017-01-26 |
EP3077504A1 (en) | 2016-10-12 |
KR20160090904A (ko) | 2016-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX371187B (es) | Péptidos terapéuticos. | |
MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
PH12016501151A1 (en) | Nrf2 regulators | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
MX2015011075A (es) | Peptidos terapeuticos. | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
MX2013015176A (es) | Co-agonistas del receptor de glucagon/glp-1. | |
CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
EA201690613A1 (ru) | Улучшенные составы на основе аденовирусов | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
NZ717192A (en) | Anti-inflammatory tripeptides | |
MX2015012905A (es) | Formulaciones de factor viii recombinantes. | |
UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
MX2016001691A (es) | Moleculas de union al receptor bag3 para uso como un medicamento. | |
BR112016007816A2 (pt) | composições peptídicas inovadoras | |
EP3083661A4 (en) | Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositions | |
MX2013008559A (es) | Derivados de leptina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |